← All trials
NCT05888857
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2023
- Primary completion
- Mar 31, 2026
- Completion date
- Sep 30, 2027
- First posted
- Jun 5, 2023
- Last posted
- Aug 4, 2023
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Institut BergoniéLead sponsor
- AstraZenecaCollaborator
- National Cancer Institute, FranceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.